Is PLX or PTHS more undervalued in 2026?

CirclFi compares Protalix BioTherapeutics, Inc. (PLX) and Pelthos Therapeutics Inc. (PTHS) using 13 institutional-grade valuation models. PLX has a Quality of Company score of 7.6/10 while PTHS scores 4.4/10.

Which is a better buy — PLX or PTHS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PLX and PTHS valuations compare?

PLX at $2.11 and PTHS at $26.47 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PLX vs PTHS Valuation Comparison 2026 — Intrinsic Value Analysis

PLX

Biological Products, (No Diagnostic Substances)

Protalix BioTherapeutics, Inc.

Quality

7.6

out of 10

Value Trap

SAFE

Price

$2.11

Last close

Models

12/13

Active

PTHS

Biological Products, (No Diagnostic Substances)

Pelthos Therapeutics Inc.

Quality

4.4

out of 10

Value Trap

LOW

Price

$26.47

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	PLX Fair Value	PLX Upside	PTHS Fair Value	PTHS Upside
Bayesian DCF	Intrinsic	$1.66	-21.2%	$9.93	-62.5%
Earnings Power Value	Intrinsic	$3.20	+51.4%	$16.77	-32.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLX vs PTHS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLX vs PTHS — Which Stock Is More Undervalued?

PLX scores higher with a 7.6/10 quality rating vs PTHS's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Protalix BioTherapeutics, Inc. (PLX) and Pelthos Therapeutics Inc. (PTHS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLX currently trades at $2.11 with a QOC of 7.6/10, while PTHS trades at $26.47 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).